Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding, Gad A. Getz, David A. Wheeler et al. · Nature · 2008
Cited by 2,678 works. doi:10.1038/nature07423 Open-access PDF
Authors
- Li Ding
- Gad A. Getz
- David A. Wheeler
- Elaine R. Mardis
- Michael D. McLellan
- Kristian Cibulskis
- Carrie L. Sougnez
- Heidi E. Greulich
- Donna Marie Muzny
- Margaret Morgan
- Lucinda Fulton
- Robert S. Fulton
- Qunyuan Zhang
- Michael C. Wendl
- Michael S. Lawrence
- David E. Larson
- Ken Chen
- David J. Dooling
- Aniko Sabo
- Alicia C. Hawes
References
- Global cancer statistics
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Global Cancer Statistics, 2002
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Mutations of the BRAF gene in human cancer
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- The Consensus Coding Sequences of Human Breast and Colorectal Cancers
- p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain